When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he’s unwaveringly honest. “Patients always ask me, “What can I hope to get out of this?” Shneider says. “And I always say, in most clinical trials, our hope is that we can slow the disease or maybe even halt progression.”
So it was a big surprise when some of the patients treated with an experimental drug — a therapy that emerged from Shneider’s research efforts –…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply